Late-life psychosis: It’s efficacy vs. cost in the tug-of-war over treatment
Current Psychiatry. 2002 July;01(07):10-18
July 1, 2002|Current Psychiatry
Author and Disclosure Information
Despite evidence of efficacy and superior safety, atypical antipsychotics are often relegated to second-line therapy. For older patients with psychotic symptoms, this cost-driven approach may increase the risks of cortical changes, decline in function, and institutionalization.
Dr. Verma reports that he is on the speakers’ bureau of Eli Lilly and Co. and Abbott Laboratories, serves as a consultant to Eli Lilly and Co., and receives grant support from Eli Lilly and Co. and GlaxoSmithKline.
